Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas.

Cancers·2026
Same author

Mononuclear, Homo- and Heterodinuclear Nickel(I) and Palladium(I) Carbonyl Complexes.

Inorganic chemistry·2026
Same author

Effects of Volume Overload: A Case Report of an Edema Bulla.

Journal of education & teaching in emergency medicine·2026
Same author

The Potential of Artificial Intelligence to Improve Selection Criteria for Liver Transplantation in HCC.

Cancers·2025
Same author

Dynamics of Metal-Metal Bond Dissociation in Pd-Pd and Ni-Ni Complexes: Reorganization and Redistribution Reactions of the Metalloradicals.

Angewandte Chemie (International ed. in English)·2025
Same author

Case Report: "<i>DEK::AFF2</i> fusion associated sinonasal carcinomas: a novel oncogenic driver and emerging therapeutic strategies".

Frontiers in immunology·2025

Related Experiment Video

Updated: Dec 20, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.4K

Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil.

Matthias Behrend1, Felix Braun

  • 1Klinik für Viszeral-, Thorax-, Gefäss- und Kinderchirurgie, Klinikum Deggendorf, Deggendorf, Germany. Matthias.Beherend@klinikum-Deggendorf.de

Drugs
|May 24, 2005
PubMed
Summary

Enteric-coated mycophenolate sodium offers similar efficacy and safety to mycophenolate mofetil in kidney transplant patients. This alternative immunosuppressant may improve compliance despite comparable gastrointestinal adverse effects.

More Related Videos

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

11.0K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.3K

Related Experiment Videos

Last Updated: Dec 20, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.4K
Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

11.0K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.3K

Area of Science:

  • Pharmacology
  • Transplantation Medicine
  • Gastroenterology

Background:

  • Mycophenolate mofetil is a common immunosuppressant in organ transplantation.
  • Gastrointestinal adverse effects of mycophenolate mofetil can reduce efficacy and compliance.
  • Enteric-coated (EC) mycophenolate sodium is a new formulation of mycophenolic acid (MPA).

Purpose of the Study:

  • To evaluate the efficacy and safety of EC mycophenolate sodium compared to mycophenolate mofetil.
  • To assess the impact of EC mycophenolate sodium on gastrointestinal adverse effects and compliance in kidney transplant recipients.

Main Methods:

  • Clinical trials comparing EC mycophenolate sodium and mycophenolate mofetil in kidney transplant recipients.
  • Analysis of efficacy rates, adverse effect profiles, and systemic MPA exposure.

Main Results:

  • EC mycophenolate sodium demonstrated similar efficacy and adverse effect rates to mycophenolate mofetil.
  • Systemic MPA exposure was higher with EC mycophenolate sodium, without increased gastrointestinal toxicity.
  • Enteric coating did not significantly reduce gastrointestinal adverse effects.

Conclusions:

  • EC mycophenolate sodium is a viable alternative to mycophenolate mofetil for kidney transplant recipients.
  • Further research on dosage, therapeutic drug monitoring, and individualized regimens is needed.
  • Improved compliance may be achievable with EC mycophenolate sodium, though GI effects remain a concern.